Article Versions Notes

Arnold WC, Panneerdoss DM, Subramani B, Mahajan M, Ebrahimi B, Ramirez P, Santhamma B, Viswanadhapalli S, Kost ER, Chen Y, et al. EC359 Enhances Trametinib Efficacy in Ras/Raf-Driven Ovarian Cancer by Suppressing LIFR Signaling. Biomolecules. 2025; 15(10):1396. https://doi.org/10.3390/biom15101396

Arnold, William C., Durga Meenakshi Panneerdoss, Baskaran Subramani, Megharani Mahajan, Behnam Ebrahimi, Paulina Ramirez, Bindu Santhamma, Suryavathi Viswanadhapalli, Edward R. Kost, Yidong Chen, and et al. 2025. "EC359 Enhances Trametinib Efficacy in Ras/Raf-Driven Ovarian Cancer by Suppressing LIFR Signaling" Biomolecules 15, no. 10: 1396. https://doi.org/10.3390/biom15101396

Arnold, W. C., Panneerdoss, D. M., Subramani, B., Mahajan, M., Ebrahimi, B., Ramirez, P., Santhamma, B., Viswanadhapalli, S., Kost, E. R., Chen, Y., Lai, Z., Nair, H. B., Vadlamudi, R. K., & Lyons, Y. A. (2025). EC359 Enhances Trametinib Efficacy in Ras/Raf-Driven Ovarian Cancer by Suppressing LIFR Signaling. Biomolecules, 15(10), 1396. https://doi.org/10.3390/biom15101396